Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
World Journal of Urology
Erschienen in: World Journal of Urology 3/2005

01.07.2005 | Topic Paper

Immunotherapy in metastatic renal cell carcinoma

verfasst von: Karl Rohrmann, Michael Staehler, Nikolas Haseke, Alexander Bachmann, Christian G. Stief, Michael Siebels

Erschienen in: World Journal of Urology | Ausgabe 3/2005

Einloggen, um Zugang zu erhalten

Abstract

Metastatic renal cell carcinoma has a poor prognosis. Conventional therapies such as chemotherapy, radiation or hormonal treatment have hardly any effect on the progression of this disease. As renal cell carcinoma seems to be an immunogenic tumor, several immunotherapeutic approaches with different response rates have been developed since the early 1990s. We present an overview of various immunotherapeutic approaches such as cytokine-based regimes, with and without different cytotoxic chemotherapy, of metastatic renal cell carcinoma. In addition, local therapies (e.g. inhalation of interleukin-2) are reviewed.
Literatur
1.
Ljungberg B (2004) Prognostic factors in renal cell carcinoma. Urologe A. 43 [Suppl 3]:119–120
2.
Pisani P, Parkin DM, Ferlay J (1993) Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 55:891
3.
Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer statistics, 1998. Cancer J Clin 48:6–29PubMed
4.
Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166:1611–1623
5.
De Kernion JB, Ramming KP, Smith RB (1978) The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 120:148–52PubMed
6.
Lam JS, Shvarts O, Figlin RA, Belldegrun AS (2004) Renal cell carcinoma 2004: new frontiers in staging, prognostication, and targeted molecular therapy. J Urol (in press)
7.
Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80:1198–1220CrossRef
8.
Figlin RA (1999) Renal cell carcinoma: management of advanced disease. J Urol 161:381–387CrossRef
9.
Young RC (1998) Metastatic renal-cell carcinoma: what causes occasional dramatic regressions? New Engl J Med 338:1305–1306
10.
Siebels M, Theodorakis J, Liedl B, Schneede P, Hofstetter A (2000) Large de novo renal cell carcinoma in a 10-year-old transplanted kidney: successful organ-preserving therapy. Transplantation 69:677–679CrossRefPubMed
11.
Feldmann JD, Jacobs SC (1992) Late development of renal carcinoma in allograft kidney. J Urol 148:395–397PubMed
12.
Williams JC, Merguerian PA, Schned AR, Morrison PM (1995) Acquired renal cystic disease and renal cell carcinoma in an allograft kidney. J Urol 152:395–396
13.
Wyczolkowski M, Klima W, Bieda W, Walas K (2001) Spontaneous regression of hepatic metastases after nephrectomy and metastasectomy of renal cell carcinoma. Urol Int 66:119–120
14.
Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 27:177–186
15.
Mickisch GH, Roehrich K, Koessig J, Forster S, Tschada RK, Alken PM (1990) Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J Urol 144:755–759
16.
Volm M, Kastel M, Mattern J, Efferth T (1993) Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 71:3981–3987
17.
Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher J (2004) Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101:1545–1551
18.
Siebels M, Oberneder R, Buchner A, Zaak D, Mack A, Petrides PE, Hofstetter A, Wowra (2002) Ambulatory radiosurgery in cerebral metastatic renal cell carcinoma. 5-year outcome in 58 patients. Urologe A 41:482–488
19.
Wowra B, Siebels M, Muacevic A, Kreth FW, Mack A, Hofstetter A (2002) Repeated gamma knife surgery for multiple brain metastases from renal cell carcinoma. J Neurosurg 97:785–793
20.
Brinkmann OA, Bruns F, Prott FJ, Hertle L (1998) Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC). Anticancer Res 19:1583–1587
21.
Fisher RI, Rosenberg SA, Sznol M (1997) High dose aldesleukin in renal cell carcinoma: long term survival update. Cancer J Sci Am 3:S70
22.
Kradin R, Kurnick J, Lazarus D, Preffer F, Dubinett S, Pinto C, Gifford J, Davidson E, Grove B, Callahan R, Strauss HW (1989) Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet: 577
23.
Rosenberg S, Lotze M, Muul L, Chang A, Avis F, Leitman S, Linehan M, Robertson C, Lee R, Rubin J, Seipp C, Simpson C, White D (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 316:890
24.
Thompson J, Shulman K, Benyunes M, Lindgren C, Collins C, Lange P, Bush W, Benz L, Fefer A (1992) Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 10:960
25.
Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick A, Lange P, Steinberg G, Belldegrun AS (1999) Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17:2521
26.
Heinzer H, Huland E, Huland H (2002) Regional immunotherapy for metastatic renal cell carcinoma. Urologe A 41:239CrossRefPubMed
27.
Huland E, Heinzer H, Timm S, Aalamian M, Huland H (2002) Immuntherapie des metastasierten Nierenzellkarzinoms in Deutschland. Eine Standortbestimmung. Der Urologe A 41:282–287
28.
Huland E, Heinzer H, Huland H (1999) Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2). Anticancer Res 19:2679–2683PubMed
29.
Rohrmann K, Schleypen J, Adam C, Hofstetter A, Siebels M (2004) Complete remission of pulmonary metastasized renal cell carcinoma after inhalative Interleukin-2 therapy. Urologe A 14:1245–1248
30.
Schleypen JS, Von Geldern M, Weiss EH, Kotzias N, Rohrmann K, Schendel DJ, Falk CS, Pohla H (2003) Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer 106:905–912CrossRefPubMed
31.
Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368
32.
Bleumer I, Oosterwijk E, De Mulder P, Mulders PFA (2003) Immunotherapy for renal cell carcinoma. Eur Urol 44:65–75PubMed
33.
Kriegmair M, Oberneder R, Hofstetter A (1995) Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 45:758
34.
Pyrrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T et al. (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17:2859–2867PubMed
35.
Sella A, Logothetis CJ, Fitz K (1992) Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. J Urol 147:573
36.
Hänninen EL, Kirchner H, Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma, risks and benefits in 215 consecutive single institution patients. J Urol 155:19PubMed
37.
Hofmockel G, Langer W, Theiss M, Gruss A, Frohmueller HG (1996) Chemoimmunotherapy for metastatic renal cell carcinoma using a regime of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol 156:18CrossRefPubMed
38.
Wadler S, Schwartz EL, Goldman M (1989) Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7:1769
39.
Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50:3473
40.
Wadler S, Wersto R, Weiberg V Thompson D, Schwartz EL (1990) Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 50:5735
41.
Negrier S, Caty A, Lesimple T, Douillard J-Y, Escudier B, Rossi J-F, Viens P, Gomez F (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 18:4009PubMed
42.
Negrier S, Escudier B, Lasset C, Douillard J-Y, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. New Engl J Med 338:1272–1278
43.
Atzpodien J, Lopez Hanninen E, Kirchner H, Franzke A, Korfer A, Volkenandt M, Duensing S, Schomburg A, Chaitchik S, Poliwoda H (1995) Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 31:876–881
44.
Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, Jurgenson S, Wandert T, Patzelt T, Reitz M (2001) IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85:1130–1136CrossRefPubMed
45.
Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, Amato RJ, Logothetis CJ (1994) Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother 9:103–111PubMed
46.
Atzpodien J, Kirchner H, Siebels M, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Wandert T, Patzelt T, Reitz M and DGCIN (2004) Interleukin-2- and Interferon-alpha2a-based Immuno-Chemotherapy in advanced renal cell carcinoma: results of a prospective randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188–1194CrossRefPubMed
47.
Cassidy J, Dirix L, Bisset D (1998) A phase I study of capecitabine in combination with oral leucovorine in patients with intractable solid tumors. Clin Cancer Res 4:2755
48.
Wenzel C, Locker GJ, Bartsch R, Pluschnig U, Mader R, Hussian D, Kramer G, Marberger M, Lintner C, Rauchenwald M, Zielinski CC, Steger GG (2003) Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Anticancer Drugs 14:779–784
49.
Stadler WM, Kuzel T, Dumas M, Vogelzang NJ (1998) Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal cell carcinoma. J Clin Oncol 16:1820
50.
Fossa SD, Mickisch GHJ, De Mulder PHM, Horenblas S, Van Oosterom AT, Van Poppel H, Fey M, Croles JJ, De Prijck L, Van Glabbeke M (2004) Interferon-alpha2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 101:533–540PubMed
51.
Ryan CW, Vogelzang NJ, Dumas M, Kuzel T, Stadler WM (2000) Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma. Cancer 88:1317
52.
Westermann J, Reich G, Kopp J, Haus U, Dörken B, Pezzutto A (2001) Granulocyte/macrophage-colony-stimulating factor plus interleukin-2 plus interferon-alpha in the treatment of metastatic renal cell carcinoma: a pilot study. Cancer Immunol Immunother 49:613
53.
Van Herpen CM, De Mulder PH (2002) Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma. Crit Rev Oncol Hematol 41:327–334
54.
Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T et al. (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972–2980
55.
Ognibene FP, Rosenberg SA, Lotze M, Skibber J, Parker MM, Shelhamer JH, Parrillo JE (1988) Interleukin-2 administration causes reversible hemodynamicchanges and left ventricular dysfunction similar to those seen in septic shock. Chest 94:750–754
56.
Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463
57.
Bretheau D, Lechevallier E, Eghazarian C, Grisoni V, Coulange C (1995) Prognostic significance of incidental renal cell carcinoma. Eur Urol 27:319–323
58.
Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970CrossRefPubMed
59.
Negrier S (2004) Better survival with interleukin-2-based regimens? Possibly only in highly selected patients. J Clin Oncol 22:1174–1176
60.
Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ (1997) Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80:2128–2132CrossRefPubMed
Metadaten
Titel
Immunotherapy in metastatic renal cell carcinoma
verfasst von
Karl Rohrmann
Michael Staehler
Nikolas Haseke
Alexander Bachmann
Christian G. Stief
Michael Siebels
Publikationsdatum
01.07.2005
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 3/2005
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-004-0470-4

Weitere Artikel der Ausgabe 3/2005

World Journal of Urology 3/2005 Zur Ausgabe

Topic Paper

Chemotherapy in metastatic renal cell cancer

Free Paper

A new technique combining both polypropylene and vaginal wall sling procedures: can it minimize the risk of urethral and vaginal erosion occurring with synthetic materials?

Topic Paper

Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells

Topic Paper

Combination of surgery and immunotherapy in metastatic renal cell carcinoma

Topic Paper

Surgery for metastatic renal cell cancer

Topic Paper

Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise